Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160 Derio, Spain.
Atlas Molecular Pharma S. L., Bizkaia Technology Park, Building 801A, 48160 Derio, Spain.
Biomolecules. 2020 Mar 19;10(3):469. doi: 10.3390/biom10030469.
Transmissible spongiform encephalopathies or prion diseases are rapidly progressive neurodegenerative diseases, the clinical manifestation of which can resemble other promptly evolving neurological maladies. Therefore, the unequivocal ante-mortem diagnosis is highly challenging and was only possible by histopathological and immunohistochemical analysis of the brain at necropsy. Although surrogate biomarkers of neurological damage have become invaluable to complement clinical data and provide more accurate diagnostics at early stages, other neurodegenerative diseases show similar alterations hindering the differential diagnosis. To solve that, the detection of the pathognomonic biomarker of disease, PrP, the aberrantly folded isoform of the prion protein, could be used. However, the amounts in easily accessible tissues or body fluids at pre-clinical or early clinical stages are extremely low for the standard detection methods. The solution comes from the recent development of in vitro prion propagation techniques, such as Protein Misfolding Cyclic Amplification (PMCA) and Real Time-Quaking Induced Conversion (RT-QuIC), which have been already applied to detect minute amounts of PrP in different matrixes and make early diagnosis of prion diseases feasible in a near future. Herein, the most relevant tissues and body fluids in which PrP has been detected in animals and humans are being reviewed, especially those in which cell-free prion propagation systems have been used with diagnostic purposes.
传染性海绵状脑病或朊病毒病是快速进展性神经退行性疾病,其临床表现类似于其他迅速发展的神经疾病。因此,明确的生前诊断极具挑战性,仅可通过尸检时对大脑进行组织病理学和免疫组织化学分析来实现。虽然神经损伤的替代生物标志物对于补充临床数据和在早期阶段提供更准确的诊断变得非常重要,但其他神经退行性疾病也表现出类似的改变,这阻碍了鉴别诊断。为了解决这个问题,可以使用疾病的标志性生物标志物 PrP 来检测,PrP 是朊病毒蛋白的异常折叠同工型。然而,在临床前或早期临床阶段,标准检测方法很难在易于获取的组织或体液中检测到极少量的 PrP。最近开发的体外朊病毒传播技术,如蛋白错误折叠循环扩增(PMCA)和实时震动诱导转化(RT-QuIC),为解决这个问题提供了方案。这些技术已经被应用于检测不同基质中极少量的 PrP,使得在不久的将来能够实现朊病毒病的早期诊断。本文综述了在动物和人类中已检测到 PrP 的最相关组织和体液,特别是那些用于诊断目的的无细胞朊病毒传播系统。